| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 132 | 2024 | 800 | 13.890 |
Why?
|
| Brain | 113 | 2025 | 707 | 10.290 |
Why?
|
| Aging | 66 | 2023 | 680 | 6.730 |
Why?
|
| Cognitive Dysfunction | 47 | 2023 | 449 | 6.050 |
Why?
|
| Dementia | 36 | 2023 | 236 | 5.570 |
Why?
|
| Aged, 80 and over | 152 | 2024 | 2152 | 4.920 |
Why?
|
| Cognition Disorders | 41 | 2018 | 437 | 4.500 |
Why?
|
| Cognition | 47 | 2024 | 641 | 3.840 |
Why?
|
| Humans | 230 | 2025 | 12240 | 3.730 |
Why?
|
| Aged | 146 | 2025 | 4000 | 3.680 |
Why?
|
| Female | 174 | 2025 | 6974 | 3.600 |
Why?
|
| Male | 173 | 2025 | 6815 | 3.590 |
Why?
|
| Lewy Body Disease | 14 | 2022 | 54 | 3.220 |
Why?
|
| DNA-Binding Proteins | 22 | 2023 | 151 | 3.190 |
Why?
|
| TDP-43 Proteinopathies | 13 | 2022 | 40 | 3.080 |
Why?
|
| Cerebrovascular Disorders | 13 | 2021 | 60 | 2.840 |
Why?
|
| Frontotemporal Lobar Degeneration | 6 | 2023 | 14 | 2.570 |
Why?
|
| Cerebral Amyloid Angiopathy | 13 | 2023 | 57 | 2.440 |
Why?
|
| Cohort Studies | 54 | 2024 | 827 | 2.390 |
Why?
|
| Genetic Predisposition to Disease | 21 | 2022 | 182 | 1.890 |
Why?
|
| Amyloid beta-Peptides | 26 | 2024 | 98 | 1.880 |
Why?
|
| Longitudinal Studies | 54 | 2023 | 651 | 1.850 |
Why?
|
| Nervous System Diseases | 9 | 2023 | 60 | 1.700 |
Why?
|
| Apolipoproteins E | 17 | 2023 | 100 | 1.570 |
Why?
|
| Parkinson Disease | 12 | 2021 | 314 | 1.560 |
Why?
|
| Brain Infarction | 7 | 2018 | 36 | 1.530 |
Why?
|
| Neurodegenerative Diseases | 7 | 2023 | 60 | 1.520 |
Why?
|
| Neuropsychological Tests | 38 | 2022 | 558 | 1.500 |
Why?
|
| Lewy Bodies | 17 | 2021 | 96 | 1.470 |
Why?
|
| Autopsy | 35 | 2023 | 174 | 1.430 |
Why?
|
| Hypertension | 3 | 2023 | 85 | 1.430 |
Why?
|
| Hippocampus | 13 | 2022 | 97 | 1.410 |
Why?
|
| Neurofibrillary Tangles | 18 | 2023 | 64 | 1.400 |
Why?
|
| Cerebral Infarction | 15 | 2020 | 63 | 1.390 |
Why?
|
| Nerve Tissue Proteins | 11 | 2022 | 87 | 1.350 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2023 | 10 | 1.330 |
Why?
|
| Plaque, Amyloid | 15 | 2023 | 45 | 1.300 |
Why?
|
| tau Proteins | 19 | 2023 | 88 | 1.260 |
Why?
|
| Membrane Proteins | 9 | 2022 | 69 | 1.160 |
Why?
|
| Genome-Wide Association Study | 21 | 2022 | 108 | 1.140 |
Why?
|
| Memory Disorders | 4 | 2018 | 68 | 1.140 |
Why?
|
| Genotype | 19 | 2023 | 169 | 1.130 |
Why?
|
| Polymorphism, Single Nucleotide | 18 | 2022 | 110 | 1.110 |
Why?
|
| Sex Characteristics | 6 | 2023 | 64 | 1.070 |
Why?
|
| Neuropathology | 11 | 2023 | 42 | 1.060 |
Why?
|
| Cerebral Cortex | 7 | 2021 | 77 | 1.030 |
Why?
|
| Apolipoprotein E4 | 11 | 2020 | 106 | 1.010 |
Why?
|
| Magnetic Resonance Imaging | 17 | 2023 | 464 | 0.940 |
Why?
|
| Dementia, Vascular | 4 | 2023 | 19 | 0.940 |
Why?
|
| Genetic Loci | 6 | 2019 | 25 | 0.930 |
Why?
|
| Risk Factors | 27 | 2023 | 1049 | 0.910 |
Why?
|
| White Matter | 4 | 2022 | 52 | 0.900 |
Why?
|
| Intracranial Arteriosclerosis | 7 | 2021 | 29 | 0.880 |
Why?
|
| Temporal Lobe | 6 | 2020 | 29 | 0.860 |
Why?
|
| Microglia | 10 | 2021 | 64 | 0.860 |
Why?
|
| Prospective Studies | 21 | 2023 | 817 | 0.830 |
Why?
|
| Follow-Up Studies | 19 | 2021 | 726 | 0.820 |
Why?
|
| Spinal Cord | 4 | 2018 | 46 | 0.810 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2023 | 2 | 0.810 |
Why?
|
| Adaptor Proteins, Signal Transducing | 5 | 2020 | 28 | 0.810 |
Why?
|
| Frontotemporal Dementia | 1 | 2023 | 2 | 0.790 |
Why?
|
| Memory | 9 | 2020 | 112 | 0.780 |
Why?
|
| alpha-Synuclein | 4 | 2020 | 59 | 0.780 |
Why?
|
| Amyloid | 6 | 2021 | 20 | 0.770 |
Why?
|
| Limbic Encephalitis | 2 | 2020 | 5 | 0.760 |
Why?
|
| Parkinsonian Disorders | 6 | 2021 | 91 | 0.740 |
Why?
|
| Independent Living | 10 | 2022 | 137 | 0.740 |
Why?
|
| DNA Methylation | 9 | 2021 | 93 | 0.740 |
Why?
|
| Transcriptome | 6 | 2022 | 32 | 0.710 |
Why?
|
| Disease Progression | 14 | 2021 | 290 | 0.690 |
Why?
|
| Proteomics | 7 | 2023 | 39 | 0.640 |
Why?
|
| Epigenesis, Genetic | 5 | 2021 | 43 | 0.590 |
Why?
|
| Cerebral Arteries | 3 | 2016 | 18 | 0.570 |
Why?
|
| Emergencies | 1 | 2019 | 26 | 0.570 |
Why?
|
| Genetic Variation | 6 | 2021 | 44 | 0.550 |
Why?
|
| Memory, Episodic | 4 | 2023 | 43 | 0.550 |
Why?
|
| Neurons | 8 | 2022 | 164 | 0.540 |
Why?
|
| Blood Pressure | 1 | 2018 | 99 | 0.530 |
Why?
|
| Alleles | 12 | 2020 | 119 | 0.530 |
Why?
|
| Middle Aged | 23 | 2025 | 4043 | 0.530 |
Why?
|
| Arteriolosclerosis | 5 | 2018 | 25 | 0.530 |
Why?
|
| Genetic Association Studies | 8 | 2020 | 45 | 0.530 |
Why?
|
| Hospitalization | 1 | 2019 | 158 | 0.520 |
Why?
|
| United States | 13 | 2021 | 989 | 0.490 |
Why?
|
| Phenotype | 9 | 2021 | 157 | 0.480 |
Why?
|
| Cognitive Aging | 3 | 2021 | 34 | 0.460 |
Why?
|
| SNARE Proteins | 3 | 2021 | 5 | 0.460 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 6 | 0.460 |
Why?
|
| Adult | 14 | 2025 | 3557 | 0.450 |
Why?
|
| Motor Activity | 4 | 2019 | 175 | 0.450 |
Why?
|
| Gene Expression | 7 | 2019 | 97 | 0.450 |
Why?
|
| Age Factors | 9 | 2021 | 350 | 0.440 |
Why?
|
| Cognitive Reserve | 3 | 2022 | 12 | 0.440 |
Why?
|
| Exercise | 4 | 2021 | 233 | 0.420 |
Why?
|
| Substantia Nigra | 3 | 2021 | 68 | 0.420 |
Why?
|
| Severity of Illness Index | 8 | 2021 | 423 | 0.420 |
Why?
|
| Synapses | 3 | 2021 | 15 | 0.420 |
Why?
|
| Brain Diseases | 3 | 2020 | 30 | 0.410 |
Why?
|
| Social Behavior | 1 | 2013 | 38 | 0.400 |
Why?
|
| Cytomegalovirus Infections | 1 | 2013 | 20 | 0.400 |
Why?
|
| Receptors, Immunologic | 3 | 2020 | 10 | 0.400 |
Why?
|
| Olfaction Disorders | 3 | 2021 | 24 | 0.400 |
Why?
|
| Membrane Glycoproteins | 3 | 2020 | 30 | 0.390 |
Why?
|
| Life Style | 1 | 2013 | 102 | 0.380 |
Why?
|
| Educational Status | 6 | 2021 | 130 | 0.370 |
Why?
|
| Genome, Human | 3 | 2018 | 21 | 0.370 |
Why?
|
| Neuropeptides | 3 | 2023 | 17 | 0.370 |
Why?
|
| Apoptosis | 1 | 2012 | 105 | 0.360 |
Why?
|
| Logistic Models | 6 | 2019 | 196 | 0.360 |
Why?
|
| Tissue Donors | 1 | 2012 | 42 | 0.360 |
Why?
|
| Animals | 13 | 2021 | 2092 | 0.360 |
Why?
|
| Biomarkers | 10 | 2025 | 294 | 0.350 |
Why?
|
| Apolipoprotein E2 | 2 | 2023 | 5 | 0.350 |
Why?
|
| Linear Models | 7 | 2020 | 115 | 0.350 |
Why?
|
| Patient Selection | 1 | 2012 | 111 | 0.350 |
Why?
|
| Antibodies, Antiphospholipid | 3 | 2019 | 19 | 0.350 |
Why?
|
| Cerebral Hemorrhage | 3 | 2023 | 37 | 0.340 |
Why?
|
| Nanomedicine | 1 | 2011 | 1 | 0.340 |
Why?
|
| Stroke | 3 | 2018 | 117 | 0.340 |
Why?
|
| Biomedical Research | 1 | 2011 | 27 | 0.340 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 5 | 3 | 2019 | 20 | 0.330 |
Why?
|
| Membrane Transport Proteins | 4 | 2022 | 33 | 0.330 |
Why?
|
| Tauopathies | 2 | 2023 | 5 | 0.330 |
Why?
|
| Sclerosis | 7 | 2021 | 32 | 0.320 |
Why?
|
| Algorithms | 4 | 2020 | 169 | 0.310 |
Why?
|
| Iron | 2 | 2021 | 13 | 0.310 |
Why?
|
| Neoplasms | 1 | 2011 | 94 | 0.310 |
Why?
|
| Sequence Analysis, RNA | 5 | 2020 | 17 | 0.310 |
Why?
|
| Frontal Lobe | 4 | 2018 | 32 | 0.310 |
Why?
|
| Neocortex | 3 | 2019 | 17 | 0.310 |
Why?
|
| Motor Disorders | 2 | 2020 | 13 | 0.310 |
Why?
|
| Folic Acid | 3 | 2006 | 15 | 0.300 |
Why?
|
| Heterozygote | 4 | 2018 | 72 | 0.300 |
Why?
|
| Vitamin B 12 | 2 | 2006 | 9 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2021 | 14 | 0.280 |
Why?
|
| Dietary Supplements | 2 | 2006 | 26 | 0.280 |
Why?
|
| Prefrontal Cortex | 3 | 2018 | 66 | 0.280 |
Why?
|
| Sulfonylurea Receptors | 2 | 2021 | 2 | 0.280 |
Why?
|
| Microvessels | 2 | 2019 | 11 | 0.280 |
Why?
|
| Health Literacy | 2 | 2020 | 45 | 0.270 |
Why?
|
| Housing for the Elderly | 1 | 2007 | 5 | 0.260 |
Why?
|
| Neuroimaging | 4 | 2021 | 66 | 0.250 |
Why?
|
| Brain Chemistry | 2 | 2020 | 22 | 0.240 |
Why?
|
| Haplotypes | 4 | 2020 | 26 | 0.240 |
Why?
|
| Interneurons | 1 | 2006 | 2 | 0.240 |
Why?
|
| Entorhinal Cortex | 1 | 2006 | 7 | 0.240 |
Why?
|
| Urinary Incontinence | 2 | 2017 | 15 | 0.240 |
Why?
|
| Polymorphism, Genetic | 3 | 2017 | 33 | 0.240 |
Why?
|
| Proteome | 3 | 2023 | 13 | 0.230 |
Why?
|
| Nuclear Proteins | 2 | 2017 | 43 | 0.230 |
Why?
|
| Comorbidity | 6 | 2021 | 209 | 0.230 |
Why?
|
| Aniline Compounds | 4 | 2013 | 14 | 0.230 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 63 | 0.220 |
Why?
|
| Food, Fortified | 1 | 2005 | 6 | 0.220 |
Why?
|
| Autoimmunity | 1 | 2025 | 8 | 0.220 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2006 | 67 | 0.220 |
Why?
|
| Immunohistochemistry | 5 | 2020 | 171 | 0.220 |
Why?
|
| Immunoglobulin G | 1 | 2025 | 38 | 0.220 |
Why?
|
| Case-Control Studies | 8 | 2019 | 256 | 0.210 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 3 | 2021 | 24 | 0.210 |
Why?
|
| Postmortem Changes | 3 | 2016 | 17 | 0.210 |
Why?
|
| LDL-Receptor Related Proteins | 3 | 2022 | 7 | 0.200 |
Why?
|
| Healthy Lifestyle | 1 | 2024 | 24 | 0.200 |
Why?
|
| Resilience, Psychological | 1 | 2023 | 13 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2023 | 20 | 0.190 |
Why?
|
| DNA | 1 | 2003 | 57 | 0.190 |
Why?
|
| Flavonols | 1 | 2022 | 5 | 0.190 |
Why?
|
| Memory, Short-Term | 2 | 2022 | 53 | 0.190 |
Why?
|
| HSP27 Heat-Shock Proteins | 2 | 2019 | 14 | 0.180 |
Why?
|
| Fatty Acids | 3 | 2018 | 20 | 0.180 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2022 | 12 | 0.180 |
Why?
|
| Ethylene Glycols | 2 | 2012 | 2 | 0.180 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 125 | 0.180 |
Why?
|
| Antibodies, Monoclonal | 2 | 2021 | 86 | 0.180 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 32 | 0.180 |
Why?
|
| Diet, Mediterranean | 1 | 2022 | 27 | 0.180 |
Why?
|
| Anthocyanins | 1 | 2022 | 5 | 0.180 |
Why?
|
| Fruit | 1 | 2022 | 18 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2022 | 20 | 0.180 |
Why?
|
| WW Domain-Containing Oxidoreductase | 1 | 2021 | 1 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2021 | 1 | 0.180 |
Why?
|
| Perception | 2 | 2019 | 42 | 0.180 |
Why?
|
| Research Design | 2 | 2012 | 79 | 0.170 |
Why?
|
| Large-Conductance Calcium-Activated Potassium Channel beta Subunits | 1 | 2021 | 1 | 0.170 |
Why?
|
| Mutation | 2 | 2020 | 175 | 0.170 |
Why?
|
| Cause of Death | 1 | 2021 | 32 | 0.170 |
Why?
|
| Cerebral Arterial Diseases | 1 | 2021 | 6 | 0.170 |
Why?
|
| Mental Status and Dementia Tests | 2 | 2019 | 36 | 0.170 |
Why?
|
| Netrins | 1 | 2021 | 1 | 0.170 |
Why?
|
| Amygdala | 1 | 2021 | 14 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 40 | 0.170 |
Why?
|
| Gait | 1 | 2023 | 195 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 4 | 0.170 |
Why?
|
| Microcirculation | 3 | 2011 | 15 | 0.170 |
Why?
|
| Databases, Factual | 2 | 2018 | 156 | 0.160 |
Why?
|
| Sleep Wake Disorders | 2 | 2019 | 58 | 0.160 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 25 | 0.160 |
Why?
|
| Serial Learning | 1 | 2020 | 4 | 0.160 |
Why?
|
| Memory and Learning Tests | 1 | 2020 | 5 | 0.160 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 50 | 0.160 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 18 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2021 | 105 | 0.160 |
Why?
|
| Mental Recall | 1 | 2020 | 24 | 0.160 |
Why?
|
| Proteins | 1 | 2020 | 33 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2020 | 16 | 0.160 |
Why?
|
| Organ Specificity | 2 | 2020 | 18 | 0.160 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 3 | 0.160 |
Why?
|
| Mental Status Schedule | 2 | 2018 | 38 | 0.160 |
Why?
|
| Brain Injuries, Traumatic | 2 | 2018 | 6 | 0.160 |
Why?
|
| Adaptation, Psychological | 1 | 2020 | 83 | 0.160 |
Why?
|
| Surveys and Questionnaires | 6 | 2023 | 546 | 0.160 |
Why?
|
| Homozygote | 1 | 2020 | 8 | 0.160 |
Why?
|
| Bromine | 1 | 2020 | 1 | 0.160 |
Why?
|
| Decision Making | 1 | 2021 | 95 | 0.160 |
Why?
|
| Amyloid Neuropathies | 1 | 2020 | 3 | 0.160 |
Why?
|
| Tuberous Sclerosis | 2 | 2017 | 11 | 0.150 |
Why?
|
| Cell Nucleus | 1 | 2020 | 42 | 0.150 |
Why?
|
| Cost of Illness | 1 | 2020 | 24 | 0.150 |
Why?
|
| Sleep Deprivation | 1 | 2019 | 15 | 0.150 |
Why?
|
| Positron-Emission Tomography | 3 | 2023 | 36 | 0.150 |
Why?
|
| Neurites | 3 | 2020 | 3 | 0.150 |
Why?
|
| Olfactory Bulb | 1 | 2019 | 7 | 0.150 |
Why?
|
| Neurocognitive Disorders | 1 | 2019 | 10 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2019 | 1 | 0.150 |
Why?
|
| Adenylate Kinase | 1 | 2019 | 5 | 0.150 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2019 | 5 | 0.150 |
Why?
|
| Literacy | 1 | 2019 | 13 | 0.150 |
Why?
|
| Vascular Diseases | 2 | 2013 | 25 | 0.150 |
Why?
|
| Gene Frequency | 3 | 2017 | 33 | 0.150 |
Why?
|
| Immunity | 1 | 2019 | 5 | 0.150 |
Why?
|
| Parietal Lobe | 1 | 2019 | 11 | 0.140 |
Why?
|
| RNA, Messenger | 2 | 2017 | 157 | 0.140 |
Why?
|
| Histones | 1 | 2018 | 13 | 0.140 |
Why?
|
| Lipids | 1 | 2019 | 28 | 0.140 |
Why?
|
| Motor Neurons | 1 | 2018 | 4 | 0.140 |
Why?
|
| Inflammation | 2 | 2019 | 124 | 0.140 |
Why?
|
| Antihypertensive Agents | 1 | 2019 | 15 | 0.140 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 3 | 0.140 |
Why?
|
| E2F Transcription Factors | 1 | 2018 | 1 | 0.140 |
Why?
|
| Movement | 1 | 2018 | 58 | 0.140 |
Why?
|
| Seasons | 1 | 2018 | 12 | 0.140 |
Why?
|
| Military Personnel | 1 | 2018 | 26 | 0.140 |
Why?
|
| Medicare | 1 | 2019 | 59 | 0.140 |
Why?
|
| Estradiol | 1 | 2018 | 26 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 6 | 0.140 |
Why?
|
| Data Interpretation, Statistical | 1 | 2018 | 40 | 0.140 |
Why?
|
| Arterioles | 2 | 2016 | 9 | 0.140 |
Why?
|
| Organ Size | 2 | 2015 | 41 | 0.140 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2015 | 7 | 0.140 |
Why?
|
| GPI-Linked Proteins | 3 | 2023 | 10 | 0.130 |
Why?
|
| Learning | 1 | 2018 | 34 | 0.130 |
Why?
|
| Veterans | 1 | 2018 | 52 | 0.130 |
Why?
|
| Linkage Disequilibrium | 4 | 2017 | 17 | 0.130 |
Why?
|
| CpG Islands | 4 | 2021 | 30 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 100 | 0.130 |
Why?
|
| Odds Ratio | 3 | 2017 | 115 | 0.130 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 6 | 0.130 |
Why?
|
| Epidemiologic Studies | 3 | 2012 | 14 | 0.130 |
Why?
|
| Incidence | 5 | 2018 | 338 | 0.130 |
Why?
|
| HIV Infections | 1 | 2020 | 256 | 0.130 |
Why?
|
| Phosphorylation | 4 | 2021 | 78 | 0.130 |
Why?
|
| Immunity, Innate | 1 | 2017 | 21 | 0.130 |
Why?
|
| Microfilament Proteins | 1 | 2017 | 15 | 0.130 |
Why?
|
| Sleep | 2 | 2019 | 155 | 0.120 |
Why?
|
| Peptide Fragments | 2 | 2014 | 27 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 37 | 0.120 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2016 | 132 | 0.120 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 2 | 2013 | 4 | 0.120 |
Why?
|
| Translational Medical Research | 1 | 2016 | 1 | 0.120 |
Why?
|
| Psychomotor Performance | 2 | 2020 | 85 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 1 | 2016 | 11 | 0.120 |
Why?
|
| Munc18 Proteins | 1 | 2015 | 2 | 0.120 |
Why?
|
| GABAergic Neurons | 1 | 2015 | 2 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 61 | 0.110 |
Why?
|
| Receptors, Complement 3b | 2 | 2016 | 8 | 0.110 |
Why?
|
| Awareness | 1 | 2015 | 21 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 7 | 0.110 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2015 | 2 | 0.110 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2015 | 4 | 0.110 |
Why?
|
| Residence Characteristics | 4 | 2018 | 87 | 0.110 |
Why?
|
| Visceral Afferents | 1 | 2015 | 3 | 0.110 |
Why?
|
| Spinal Cord Dorsal Horn | 1 | 2015 | 7 | 0.110 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2015 | 4 | 0.110 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2015 | 2 | 0.110 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2015 | 7 | 0.110 |
Why?
|
| Multiple System Atrophy | 1 | 2015 | 22 | 0.110 |
Why?
|
| Antiporters | 1 | 2015 | 4 | 0.110 |
Why?
|
| HLA-DRB5 Chains | 1 | 2015 | 4 | 0.110 |
Why?
|
| Quantitative Trait Loci | 3 | 2020 | 19 | 0.110 |
Why?
|
| Frail Elderly | 1 | 2014 | 19 | 0.110 |
Why?
|
| alpha-Tocopherol | 1 | 2014 | 7 | 0.100 |
Why?
|
| gamma-Tocopherol | 1 | 2014 | 7 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2014 | 9 | 0.100 |
Why?
|
| Cell Count | 4 | 2021 | 38 | 0.100 |
Why?
|
| Language | 1 | 2013 | 30 | 0.100 |
Why?
|
| Presenilin-1 | 1 | 2013 | 3 | 0.100 |
Why?
|
| Circadian Rhythm | 1 | 2015 | 122 | 0.100 |
Why?
|
| Longevity | 1 | 2013 | 15 | 0.100 |
Why?
|
| Ubiquitin | 3 | 2008 | 20 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2020 | 205 | 0.100 |
Why?
|
| Monocytes | 1 | 2013 | 23 | 0.100 |
Why?
|
| Synucleins | 1 | 2013 | 3 | 0.100 |
Why?
|
| Psychomotor Disorders | 1 | 2013 | 8 | 0.100 |
Why?
|
| Rats | 3 | 2021 | 407 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 400 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 38 | 0.090 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 12 | 0.090 |
Why?
|
| Quality of Life | 1 | 2015 | 261 | 0.090 |
Why?
|
| Atrophy | 1 | 2012 | 29 | 0.090 |
Why?
|
| Movement Disorders | 1 | 2012 | 32 | 0.090 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 81 | 0.090 |
Why?
|
| RNA | 3 | 2018 | 18 | 0.090 |
Why?
|
| Cholesterol Ester Transfer Proteins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Radiopharmaceuticals | 1 | 2012 | 27 | 0.090 |
Why?
|
| Actigraphy | 3 | 2018 | 41 | 0.090 |
Why?
|
| Apolipoprotein E3 | 2 | 2023 | 8 | 0.090 |
Why?
|
| China | 1 | 2011 | 25 | 0.090 |
Why?
|
| Receptor, EphA1 | 1 | 2011 | 1 | 0.080 |
Why?
|
| Cytoskeletal Proteins | 1 | 2011 | 4 | 0.080 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 4 | 0.080 |
Why?
|
| Peptidylprolyl Isomerase | 2 | 2010 | 4 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2011 | 28 | 0.080 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 72 | 0.080 |
Why?
|
| Statistics as Topic | 4 | 2017 | 51 | 0.080 |
Why?
|
| Cerebral Ventricles | 1 | 2011 | 11 | 0.080 |
Why?
|
| Vitamin E | 1 | 2011 | 23 | 0.080 |
Why?
|
| Motor Skills | 2 | 2021 | 32 | 0.080 |
Why?
|
| Risk | 4 | 2016 | 97 | 0.080 |
Why?
|
| Retrospective Studies | 3 | 2022 | 1467 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2010 | 2 | 0.080 |
Why?
|
| Inclusion Bodies | 1 | 2010 | 6 | 0.080 |
Why?
|
| Brain Mapping | 3 | 2018 | 59 | 0.080 |
Why?
|
| Formaldehyde | 1 | 2009 | 5 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 15 | 0.070 |
Why?
|
| Nerve Net | 2 | 2019 | 22 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2017 | 161 | 0.070 |
Why?
|
| Lipid Metabolism | 2 | 2019 | 23 | 0.070 |
Why?
|
| Cell Line | 2 | 2019 | 150 | 0.070 |
Why?
|
| Astrocytes | 2 | 2020 | 70 | 0.070 |
Why?
|
| Carbon-Nitrogen Lyases | 1 | 2008 | 2 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2021 | 225 | 0.070 |
Why?
|
| Protein Interaction Maps | 2 | 2018 | 7 | 0.070 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 97 | 0.070 |
Why?
|
| Depression | 2 | 2021 | 229 | 0.070 |
Why?
|
| Neurologic Examination | 2 | 2020 | 49 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2007 | 24 | 0.060 |
Why?
|
| Diagnosis | 2 | 2017 | 8 | 0.060 |
Why?
|
| Probability | 2 | 2020 | 45 | 0.060 |
Why?
|
| Congresses as Topic | 2 | 2018 | 16 | 0.060 |
Why?
|
| Analysis of Variance | 2 | 2021 | 125 | 0.060 |
Why?
|
| Loneliness | 1 | 2007 | 31 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2006 | 24 | 0.060 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 3 | 0.060 |
Why?
|
| Vitamin B Complex | 1 | 2006 | 3 | 0.060 |
Why?
|
| Trans Fatty Acids | 1 | 2006 | 4 | 0.060 |
Why?
|
| Copper | 1 | 2006 | 11 | 0.060 |
Why?
|
| Genetic Testing | 2 | 2019 | 29 | 0.060 |
Why?
|
| NADPH Dehydrogenase | 1 | 2006 | 2 | 0.060 |
Why?
|
| Receptors, GABA | 1 | 2006 | 2 | 0.060 |
Why?
|
| Dietary Fats | 1 | 2006 | 26 | 0.060 |
Why?
|
| Cell Death | 1 | 2006 | 22 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2006 | 21 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 363 | 0.060 |
Why?
|
| Geriatric Assessment | 2 | 2017 | 96 | 0.060 |
Why?
|
| Time Factors | 2 | 2020 | 695 | 0.060 |
Why?
|
| Maze Learning | 2 | 2016 | 5 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 23 | 0.060 |
Why?
|
| Social Support | 1 | 2006 | 98 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 47 | 0.060 |
Why?
|
| Heme Oxygenase-1 | 1 | 2005 | 3 | 0.060 |
Why?
|
| Neopterin | 1 | 2025 | 4 | 0.060 |
Why?
|
| Glycosylation | 1 | 2025 | 12 | 0.060 |
Why?
|
| Neuroglia | 1 | 2005 | 19 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 19 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2025 | 29 | 0.050 |
Why?
|
| Data Collection | 1 | 2005 | 40 | 0.050 |
Why?
|
| Models, Statistical | 1 | 2005 | 60 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2006 | 246 | 0.050 |
Why?
|
| Endophenotypes | 2 | 2015 | 2 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 179 | 0.050 |
Why?
|
| Lumbar Vertebrae | 2 | 2018 | 182 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 186 | 0.050 |
Why?
|
| Pandemics | 1 | 2025 | 126 | 0.050 |
Why?
|
| Chicago | 1 | 2005 | 453 | 0.050 |
Why?
|
| Workflow | 1 | 2023 | 3 | 0.050 |
Why?
|
| Nerve Growth Factors | 1 | 2023 | 17 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2003 | 1 | 0.050 |
Why?
|
| Pan troglodytes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Hand Strength | 1 | 2023 | 24 | 0.050 |
Why?
|
| Evolution, Molecular | 1 | 2003 | 3 | 0.050 |
Why?
|
| Radionuclide Imaging | 2 | 2013 | 21 | 0.050 |
Why?
|
| Vitamins | 1 | 2022 | 9 | 0.050 |
Why?
|
| Age of Onset | 2 | 2014 | 46 | 0.050 |
Why?
|
| Quercetin | 1 | 2022 | 5 | 0.050 |
Why?
|
| Kaempferols | 1 | 2022 | 5 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2003 | 20 | 0.050 |
Why?
|
| Vitamin D | 1 | 2022 | 10 | 0.050 |
Why?
|
| Mice | 2 | 2016 | 760 | 0.050 |
Why?
|
| Machine Learning | 1 | 2023 | 31 | 0.050 |
Why?
|
| Eating | 1 | 2022 | 25 | 0.050 |
Why?
|
| Stem Cells | 1 | 2022 | 17 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 29 | 0.050 |
Why?
|
| Thiazoles | 2 | 2013 | 8 | 0.050 |
Why?
|
| Walking | 1 | 2023 | 108 | 0.040 |
Why?
|
| Self Stimulation | 1 | 2002 | 5 | 0.040 |
Why?
|
| Individuality | 1 | 2022 | 11 | 0.040 |
Why?
|
| Parahippocampal Gyrus | 1 | 2002 | 2 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 277 | 0.040 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2021 | 4 | 0.040 |
Why?
|
| Synaptotagmins | 1 | 2021 | 2 | 0.040 |
Why?
|
| Synapsins | 1 | 2021 | 3 | 0.040 |
Why?
|
| Synaptophysin | 1 | 2021 | 6 | 0.040 |
Why?
|
| Qa-SNARE Proteins | 1 | 2021 | 3 | 0.040 |
Why?
|
| Brazil | 1 | 2021 | 17 | 0.040 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 252 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2023 | 221 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 2 | 2014 | 4 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 4 | 0.040 |
Why?
|
| Off-Label Use | 1 | 2021 | 4 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 10 | 0.040 |
Why?
|
| Causality | 1 | 2021 | 22 | 0.040 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 20 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2020 | 5 | 0.040 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2020 | 4 | 0.040 |
Why?
|
| Vesicular Transport Proteins | 1 | 2020 | 6 | 0.040 |
Why?
|
| Actinin | 1 | 2020 | 7 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2020 | 8 | 0.040 |
Why?
|
| Epoxide Hydrolases | 1 | 2020 | 7 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 28 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 2 | 0.040 |
Why?
|
| Computational Biology | 1 | 2020 | 11 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 28 | 0.040 |
Why?
|
| Lysosomes | 1 | 2020 | 13 | 0.040 |
Why?
|
| Epistasis, Genetic | 1 | 2020 | 3 | 0.040 |
Why?
|
| Myelin Sheath | 1 | 2020 | 11 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 214 | 0.040 |
Why?
|
| Young Adult | 2 | 2013 | 863 | 0.040 |
Why?
|
| Child | 2 | 2013 | 614 | 0.040 |
Why?
|
| Axons | 1 | 2020 | 10 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2020 | 12 | 0.040 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 19 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 53 | 0.040 |
Why?
|
| Substrate Specificity | 1 | 2019 | 10 | 0.040 |
Why?
|
| COS Cells | 1 | 2019 | 22 | 0.040 |
Why?
|
| Protein Binding | 1 | 2019 | 70 | 0.040 |
Why?
|
| Nerve Growth Factor | 1 | 2019 | 25 | 0.040 |
Why?
|
| Neprilysin | 1 | 2019 | 3 | 0.040 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2019 | 2 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 295 | 0.040 |
Why?
|
| HIV-1 | 1 | 2020 | 143 | 0.040 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2012 | 30 | 0.040 |
Why?
|
| Renin-Angiotensin System | 1 | 2019 | 3 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 170 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2019 | 53 | 0.040 |
Why?
|
| Metabolomics | 1 | 2018 | 6 | 0.040 |
Why?
|
| Metabolome | 1 | 2018 | 3 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2018 | 60 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 16 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 20 | 0.040 |
Why?
|
| Oxidative Phosphorylation | 1 | 2018 | 2 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2018 | 14 | 0.040 |
Why?
|
| Reproduction | 1 | 2018 | 4 | 0.040 |
Why?
|
| DNA Repair | 1 | 2018 | 5 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2018 | 8 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2018 | 6 | 0.030 |
Why?
|
| Fractals | 1 | 2018 | 11 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 28 | 0.030 |
Why?
|
| National Institute on Aging (U.S.) | 1 | 2018 | 2 | 0.030 |
Why?
|
| Community Health Planning | 1 | 2018 | 7 | 0.030 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2017 | 8 | 0.030 |
Why?
|
| alpha-Macroglobulins | 1 | 2017 | 12 | 0.030 |
Why?
|
| Exome | 1 | 2017 | 4 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2017 | 18 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2017 | 80 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2017 | 4 | 0.030 |
Why?
|
| Vesicular Inhibitory Amino Acid Transport Proteins | 1 | 2016 | 2 | 0.030 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Presynaptic Terminals | 1 | 2016 | 5 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2016 | 8 | 0.030 |
Why?
|
| Consciousness Disorders | 1 | 2016 | 5 | 0.030 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2016 | 2 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2016 | 8 | 0.030 |
Why?
|
| Phosphatidylinositol-3,4,5-Trisphosphate 5-Phosphatases | 1 | 2016 | 4 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2016 | 22 | 0.030 |
Why?
|
| Zinc Fingers | 1 | 2016 | 10 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2016 | 105 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2016 | 28 | 0.030 |
Why?
|
| Chromatin | 1 | 2016 | 10 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2016 | 5 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 55 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 15 | 0.030 |
Why?
|
| Sacrum | 1 | 2015 | 11 | 0.030 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 5 | 0.030 |
Why?
|
| Long-Term Potentiation | 1 | 2015 | 9 | 0.030 |
Why?
|
| Sweden | 1 | 2015 | 7 | 0.030 |
Why?
|
| Protective Factors | 1 | 2015 | 10 | 0.030 |
Why?
|
| Pedigree | 1 | 2015 | 27 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 47 | 0.030 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2014 | 1 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2014 | 4 | 0.030 |
Why?
|
| Societies | 1 | 2014 | 4 | 0.030 |
Why?
|
| beta 2-Glycoprotein I | 1 | 2014 | 6 | 0.030 |
Why?
|
| Phosphatidylserines | 1 | 2014 | 6 | 0.030 |
Why?
|
| Lupus Coagulation Inhibitor | 1 | 2014 | 6 | 0.030 |
Why?
|
| Autoantigens | 1 | 2014 | 10 | 0.030 |
Why?
|
| N-Acetylgalactosaminyltransferases | 1 | 2014 | 1 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 57 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 13 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 46 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 229 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2014 | 1 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 4 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 10 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 338 | 0.030 |
Why?
|
| HLA-D Antigens | 1 | 2013 | 1 | 0.020 |
Why?
|
| Dextrans | 1 | 2013 | 2 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2013 | 25 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2013 | 117 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2012 | 6 | 0.020 |
Why?
|
| Cadaver | 1 | 2013 | 166 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2013 | 89 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2012 | 8 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 14 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2012 | 7 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 320 | 0.020 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2012 | 1 | 0.020 |
Why?
|
| Autoradiography | 1 | 2012 | 5 | 0.020 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2012 | 9 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 324 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2011 | 2 | 0.020 |
Why?
|
| Visual Perception | 1 | 2011 | 14 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2011 | 26 | 0.020 |
Why?
|
| Nutritional Status | 1 | 2011 | 33 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2011 | 2 | 0.020 |
Why?
|
| Multigene Family | 1 | 2011 | 5 | 0.020 |
Why?
|
| Social Environment | 1 | 2011 | 38 | 0.020 |
Why?
|
| Phenanthrolines | 1 | 2010 | 3 | 0.020 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 4 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 153 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 28 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 193 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2011 | 62 | 0.020 |
Why?
|
| Neurofibrils | 1 | 2010 | 1 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 989 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 28 | 0.020 |
Why?
|
| Gliosis | 1 | 2009 | 6 | 0.020 |
Why?
|
| Encephalitis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Fixatives | 1 | 2009 | 4 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 1478 | 0.020 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2009 | 10 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2009 | 18 | 0.020 |
Why?
|
| Transglutaminases | 1 | 2008 | 2 | 0.020 |
Why?
|
| GTP-Binding Proteins | 1 | 2008 | 4 | 0.020 |
Why?
|
| Motor Neuron Disease | 1 | 2007 | 3 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2007 | 5 | 0.020 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Microtubules | 1 | 2007 | 18 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 68 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 62 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2007 | 31 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2007 | 46 | 0.020 |
Why?
|
| Social Isolation | 1 | 2007 | 15 | 0.020 |
Why?
|
| Diet Surveys | 1 | 2006 | 12 | 0.020 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 23 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2006 | 218 | 0.010 |
Why?
|
| Interpersonal Relations | 1 | 2006 | 48 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 116 | 0.010 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 68 | 0.010 |
Why?
|
| Diet | 1 | 2006 | 104 | 0.010 |
Why?
|